Clinical Trials Show Efficacy of Adagrasib in Patients with NSCLC and Brain Metastases

Web Exclusives —January 26, 2023

Categories:

Lung Cancer

KRAS G12C mutation is found in 14% of patients with non–small-cell lung cancer (NSCLC) with adenocarcinoma and 0.5% to 4% of patients with squamous carcinoma. Central nervous system (CNS) metastases are found in 27% to 42% of patients with KRAS G12C NSCLC at diagnosis, which conveys a poor patient prognosis. Adagrasib is an oral small molecule that inhibits KRAS G12C by binding and locking it into an inactive form, thereby blocking KRAS signaling and exerting an antitumor effect.

An article published by Tian and colleagues discussed the findings of various clinical trials of adagrasib, focusing on its ability to penetrate the CNS. The KRYSTAL-1 clinical trial investigated the use of 600 mg of adagrasib twice daily in 116 patients with unresectable or metastatic KRAS G12C NSCLC previously treated with ≥1 platinum-based chemotherapy and immune checkpoint therapy. Treatment-related adverse events were found in 97.4% of patients, with gastrointestinal-related events being the most common. Despite this high rate of adverse events, treatment discontinuation was low—6.9%. This treatment regimen demonstrated good efficacy with acceptable safety and can offer a novel treatment for patients with KRAS G12C–mutated NSCLC.

Sotorasib was the first FDA-approved KRAS G12C inhibitor for patients with KRAS G12C NSCLC. When comparing adagrasib data with sotorasib data, Tian and colleagues found an objective response rate (ORR) of 42.9% for adagrasib, whereas sotorasib had an ORR of 37.1%. The median overall survival (OS) for sotorasib was 12.5 months with a progression-free survival (PFS) of 6.8 months. For adagrasib, the median OS was 12.6 months, and PFS was 6.5 months.

In KRYSTAL-1, CNS metastases were found in 42 patients receiving adagrasib at baseline, with a median intracranial PFS of 5.4 months. Radiographic evaluation was performed for 33 patients, and investigators found an intracranial confirmed ORR of 33.3% and a median duration of intracranial response of 11.2 months. A previous study found that sotorasib resulted in a 13% intracranial response in 16 patients with KRAS G12C NSCLC with CNS metastases.

At the 2022 American Society of Clinical Oncology Annual Meeting, the results of a phase 1b cohort of patients with NSCLC and active, untreated CNS metastases receiving adagrasib demonstrated an intracranial ORR of 32% with an intracranial disease control rate of 84%. A 2022 meta-analysis found that anti–PD-L1 therapy with or without chemotherapy resulted in a more prolonged survival than chemotherapy alone for KRAS-driven NSCLC. Despite these findings, a preclinical study found that combining a KRAS G12C inhibitor with immune checkpoint inhibitors was not successful universally, suggesting that not all patients will benefit from this treatment regimen, necessitating the further study of patient selection for successful therapy.

Source: Tian H, Yang Z, He J. Adagrasib: a landmark in the KRASG12C-mutated NSCLC. MedComm (2020). 2022;3(4):e190.

Related Articles
Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer
Web Exclusives
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
NGS Testing More Cost-Effective Than SGT in Oncology
Web Exclusives
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials
Web Exclusives
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country